Gsk
FDA import alert and refusal historyColeford, United KingdomFEI 3013386664
Recorded by FDA as GSK
As of October 26, 2026, Gsk is not on any FDA import alert in SupplierRadar's records; FDA refused 1 of its shipment line on May 2, 2018, most often for color additive unsafe under section 721 (UNSAFE COL).
Data from FDA public records, last checked . Request a correction
Current status
- Import alerts
- Not listed
- Last import refusal
- Currants, black, juice or concentrates · UNSAFE COL
- Last warning letter
- None found
- Last inspection
- None on record
Every FDA record for Gsk
1 record, newest first. Each line links to the FDA page it came from.
2018
- Import refusalRefused, Currants, black, juice or concentratesUNSAFE COLEntry KM6-3513180-8Source
Refusal charges, in plain English
- UNSAFE COL1 refused line
Color additive unsafe under section 721
The product appeared to be, or to contain, a color additive that is unsafe within the meaning of section 721(a) of the FD&C Act, the section that governs which color additives may be used and how.
Questions about Gsk
- Is Gsk on an FDA import alert?
- No listing for Gsk appears in the FDA import alerts SupplierRadar checked on October 26, 2026. Country-wide alerts may still apply to its products; see the United Kingdom page.
- Has FDA refused shipments from Gsk?
- Yes. FDA refused 1 shipment line from Gsk on May 2, 2018. The most recent, on May 2, 2018, was currants, black, juice or concentrates, charged as UNSAFE COL (color additive unsafe under section 721).
- Why did FDA refuse Gsk's shipments?
- The most frequent charge is UNSAFE COL (color additive unsafe under section 721, 1 line).
- What is Gsk's FEI number?
- Gsk's FDA Establishment Identifier (FEI) is 3013386664.
Buying from Gsk?
Watch it and get the FDA record the day it changes. Free for one supplier.
SupplierRadar is not affiliated with the U.S. Food and Drug Administration. Data comes from public FDA records and may contain errors. This is not legal advice; importers remain responsible for their supplier evaluations.